Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Safety, PK and Efficacy of TNP-2198 in Asymptomatic H. pylori Infection
NCT06081712Phase 1Completed
- Sponsor
- TenNor Therapeutics
- Start
- Oct 2020
- Primary completion
- Jul 2021
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, randomised, double-blind trial of rifasutenizol in Helicobacter pylori infection (3 arms), sponsored by TenNor Therapeutics. Primary endpoint: Incidence of Adverse Events up to 17 days. Started Oct 2020; status: completed.
02
Drugs
rifasutenizol
03
Conditions
Helicobacter pylori infection
Beyond the preview
Go deeper on NCT06081712.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06081712.